Myovant Sciences Ltd.’s recently made public that its Chief Commercial Officer Merendino Lauren unloaded Company’s shares for reported $42916.0 on Oct 18. In the deal valued at $25.20 per share,1,703 shares were sold. As a result of this transaction, Merendino Lauren now holds 171,546 shares worth roughly $ 4.58 million.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
Then, Marek David C sold 11,156 shares, generating $281,131 in total proceeds. Upon selling the shares at $25.20, the Principal Executive Officer now owns 425,636 shares.
Before that, Lang Matthew sold 1,933 shares. Myovant Sciences Ltd. shares valued at $48,712 were divested by the General Counsel & Corp. Secy. at a price of $25.20 per share. As a result of the transaction, Lang Matthew now holds 358,354 shares, worth roughly $9.56 million.
Evercore ISI downgraded its Myovant Sciences Ltd. [MYOV] rating to an In-line from a an Outperform in a research note published on Monday. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who increased its forecast for the stock in early August from “a Mkt perform” to “an Outperform”. SVB Leerink began covering MYOV with “Mkt perform” recommendation on September 09, 2021.
Price Performance Review of MYOV
On Monday, Myovant Sciences Ltd. [NYSE:MYOV] saw its stock jump 0.11% to $26.68. On the same session, the stock had its day’s lowest price of $26.65, but rose to a high of $26.72. Over the last five days, the stock has lost -0.22%. Myovant Sciences Ltd. shares have risen nearly 71.36% since the year began. Nevertheless, the stocks have risen 17.48% over the past one year. While a 52-week high of $26.84 was reached on 10/24/22, a 52-week low of $7.67 was recorded on 05/09/22. SMA at 50 days reached $21.99, while 200 days put it at $14.98. A total of 1.73 million shares were traded, compared to the trading of 3.17 million shares in the previous session.
Levels Of Support And Resistance For MYOV Stock
The 24-hour chart illustrates a support level at 26.65, which if violated will result in even more drops to 26.61. On the upside, there is a resistance level at 26.72. A further resistance level may holdings at 26.75. The Relative Strength Index (RSI) on the 14-day chart is 70.04, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 5.54%. Stochastics %K at 94.46% indicates the stock is a selling.
How much short interest is there in Myovant Sciences Ltd.?
A steep rise in short interest was recorded in Myovant Sciences Ltd. stocks on Oct 13, 2022, dropping by -0.17 million shares to a total of 3.12 million shares. Yahoo Finance data shows the prior-month short interest on Sep 14, 2022 was 3.29 million shares. There was a decline of -5.45%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 6.74% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.66.
Myovant Sciences Ltd. [MYOV] – Who Are The Largest Shareholders?
In filings from Wellington Management Co. LLP, it is revealed that the company now owns 6,416,368 shares, or roughly 6.69% of the outstanding MYOV shares. In other words, the investor’s shares have risen by 634,744 from its previous 13-F filing of 5781624.0. Additionally, Bellevue Asset Management AG increased 1.03% of its stake after which the total value it holdings stand at $106,316,716, while Janus Henderson Investors US LLC reduced -2.22% of its stake to hold $97.74 million in the firm. Over the last quarter, SSgA Funds Management, Inc. sold -1,103,581 shares of Myovant Sciences Ltd., while BlackRock Fund Advisors sold -54,676 shares. At present, Citadel Advisors LLC is holding 857,731 shares valued at $15.4 million. The Vanguard Group, Inc. owned 810,483 shares of the company at the time of its most recent 13F filing, worth $14.56 million.
According to FactSet, Myovant Sciences Ltd.’s share price will average $27.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1.31 percent from its previous closing price of $26.65. Analysts expect Myovant Sciences Ltd. stock to reach the higher price of $27.00, while the lowest price estimate is $27.00. However, 4 analysts have rated MYOV stock as a Hold in their predictions for 2022.